Table 1 Characteristics of eligible clinical trials (N=406)
Severe (N=108) | Non-severe (N=298) | |
|---|---|---|
Regiona | ||
Single region | 68 (63.0%) | 226 (75.8%) |
Multi-region | 21 (19.4%) | 23 (7.7%) |
Unknown | 19 (17.6%) | 49 (16.4%) |
Countriesa | ||
Canada | 4 (3.7%) | 19 (6.4%) |
USA | 35 (32.4%) | 58 (19.5%) |
France | 10 (9.3%) | 31 (10.4%) |
Germany | 8 (7.4%) | 9 (3.0%) |
Italy | 5 (4.6%) | 16 (5.4%) |
Russia | 9 (8.3%) | 11 (3.7%) |
Spain | 11 (10.2%) | 18 (6.0%) |
UK | 11 (10.2%) | 13 (4.4%) |
China | 3 (2.8%) | 9 (3.0%) |
Japan | 6 (5.6%) | 6 (2.0%) |
Brazil | 14 (13.0%) | 22 (7.4%) |
Others | 40 (37.0%) | 124 (41.6%) |
Number of endpoints | ||
Mean (SD) | 12.8 (10.7) | 9.0 (7.7) |
Median (IQR) | 9 (6, 16.3) | 7 (4, 12) |
Number of primary endpointsa | ||
1 | 86 (79.6%) | 216 (72.5%) |
2 | 13 (12.0%) | 42 (14.1%) |
≥3 | 9 (8.3%) | 40 (13.4%) |
Number of armsa | ||
1b | 18 (16.7%) | 63 (21.1%) |
2b | 64 (59.3%) | 177 (59.4%) |
≥3b | 26 (24.1%) | 58 (19.5%) |
Sample size (trials with 1 armb) | ||
Mean (SD) | 367.8 (378.2) | 396.3 (553.2) |
Median (IQR) | 205 (100, 462) | 200 (100, 466) |
Sample size (trials with 2 armsb) | ||
Mean (SD) | 519.2 (652.9) | 576.9 (831.3) |
Median (IQR) | 372 (230, 600) | 300 (108, 690) |
Sample size (trials with ≥3 armsb) | ||
Mean (SD) | 806.6 (787.3) | 1149.1 (2433.9) |
Median (IQR) | 475 (200, 1116) | 305 (200, 700) |